RATe Control in Atrial Fibrillation
RATAF
Rate Control in Atrial Fibrillation
1 other identifier
interventional
80
1 country
1
Brief Summary
The purpose of this study is to compare the effect of metoprolol, verapamil, diltiazem and carvedilol on ventricular rate, working capacity and quality of life in patients with chronic atrial fibrillation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3 atrial-fibrillation
Started Apr 2006
Typical duration for phase_3 atrial-fibrillation
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
April 10, 2006
CompletedFirst Posted
Study publicly available on registry
April 12, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedMay 13, 2014
May 1, 2014
4.4 years
April 10, 2006
May 11, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ventricular rate
Ventricular rate evaluated after three weeks on study drug treatment
Three weeks
Study Arms (4)
Metoprolol
ACTIVE COMPARATORTreatment with Metoprolol 100 mg x 1 for three weeks
Diltiazem
ACTIVE COMPARATORTreatment with Diltiazem 360 mg x 1 for three weeks
Verapamil
ACTIVE COMPARATORTreatment with Verapamil 240 mg x 1 for three weeks
Carvedilol
ACTIVE COMPARATORTreatment with Carvedilol 25 mg x 1 for three weeks
Interventions
Eligibility Criteria
You may qualify if:
- Persistent or permanent atrial fibrillation with ventricular rate \> 80/min at rest and/or \> 100/min average at daytime.
- Male or female, age \> 18.
You may not qualify if:
- Hypersensitivity or contraindication to metoprolol, verapamil, diltiazem or carvedilol.
- Coronary heart disease or heart failure
- Systolic blood pressure \< 100 mmHg
- AV-conduction disturbance
- Severe hepatic or renal dysfunction
- Thyrotoxicosis
- Ongoing treatment with Digitalis
- Pregnancy or lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vestre Viken Hospital Trust, Baerum Hospital
Rud, Akershus, 1309, Norway
Related Publications (3)
Horjen AW, Ulimoen SR, Enger S, Norseth J, Seljeflot I, Arnesen H, Tveit A. Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing. BMC Cardiovasc Disord. 2016 May 4;16:79. doi: 10.1186/s12872-016-0255-x.
PMID: 27142292DERIVEDCorino VD, Sandberg F, Platonov PG, Mainardi LT, Ulimoen SR, Enger S, Tveit A, Sornmo L. Non-invasive evaluation of the effect of metoprolol on the atrioventricular node during permanent atrial fibrillation. Europace. 2014 Nov;16 Suppl 4:iv129-iv134. doi: 10.1093/europace/euu246.
PMID: 25362163DERIVEDUlimoen SR, Enger S, Norseth J, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Improved rate control reduces cardiac troponin T levels in permanent atrial fibrillation. Clin Cardiol. 2014 Jul;37(7):422-7. doi: 10.1002/clc.22281. Epub 2014 Apr 3.
PMID: 24700386DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sara Reinvik Fagertun, MD
Asker and Baerum Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
April 10, 2006
First Posted
April 12, 2006
Study Start
April 1, 2006
Primary Completion
September 1, 2010
Study Completion
September 1, 2010
Last Updated
May 13, 2014
Record last verified: 2014-05